316 related articles for article (PubMed ID: 29606053)
1. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
3. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
4. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
6. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
8. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
9. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
10. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1.
Sievers P; Sill M; Blume C; Tauziede-Espariat A; Schrimpf D; Stichel D; Reuss DE; Dogan H; Hartmann C; Mawrin C; Hasselblatt M; Stummer W; Schick U; Hench J; Frank S; Ketter R; Schweizer L; Schittenhelm J; Puget S; Brandner S; Jaunmuktane Z; Küsters B; Abdullaev Z; Pekmezci M; Snuderl M; Ratliff M; Herold-Mende C; Unterberg A; Aldape K; Ellison DW; Wesseling P; Reifenberger G; Wick W; Perry A; Varlet P; Pfister SM; Jones DTW; von Deimling A; Sahm F;
Acta Neuropathol; 2021 Feb; 141(2):281-290. PubMed ID: 33319313
[TBL] [Abstract][Full Text] [Related]
11. Germline and somatic mutations in meningiomas.
Smith MJ
Cancer Genet; 2015 Apr; 208(4):107-14. PubMed ID: 25857641
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis of spinal meningiomas: correlation with histopathological grade.
Driver J; Santagata S; Bi WL; Chi JH
J Neurosurg Spine; 2023 Dec; 39(6):729-733. PubMed ID: 37728381
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF chromatin remodeling complex alterations in meningioma.
Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
[TBL] [Abstract][Full Text] [Related]
15. WHO grade III meningioma: De novo tumors show improved progression free survival as compared to secondary progressive tumors.
Ruzevick J; Gibson A; Tatman P; Emerson S; Ferreira M
J Clin Neurosci; 2021 Sep; 91():105-109. PubMed ID: 34373013
[TBL] [Abstract][Full Text] [Related]
16. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1 mutations are not a common cause of multiple meningiomas.
Hadfield KD; Smith MJ; Trump D; Newman WG; Evans DG
J Med Genet; 2010 Aug; 47(8):567-8. PubMed ID: 20472658
[TBL] [Abstract][Full Text] [Related]
18. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
19. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules.
Torres-Martín M; Kusak ME; Isla A; Burbano RR; Pinto GR; Melendez B; Castresana JS; Rey JA
Cancer Genet; 2015 Jun; 208(6):327-32. PubMed ID: 25981829
[TBL] [Abstract][Full Text] [Related]
20. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Shankar GM; Abedalthagafi M; Vaubel RA; Merrill PH; Nayyar N; Gill CM; Brewster R; Bi WL; Agarwalla PK; Thorner AR; Reardon DA; Al-Mefty O; Wen PY; Alexander BM; van Hummelen P; Batchelor TT; Ligon KL; Ligon AH; Meyerson M; Dunn IF; Beroukhim R; Louis DN; Perry A; Carter SL; Giannini C; Curry WT; Cahill DP; Barker FG; Brastianos PK; Santagata S
Neuro Oncol; 2017 Apr; 19(4):535-545. PubMed ID: 28170043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
